Prevention, Early Detection, and Interception最新文献

{"title":"Abstract 3801: Oxidative stress induces glutamine-dependent GD2+triple negative breast cancer stem cells","authors":"Appalaraju Jaggupilli, Stanely J. Ly, Roshan Borkar, K. Nguyen, Bin Yuan, N. Putluri, M. Andreeff, V. Battula","doi":"10.1158/1538-7445.am2020-3801","DOIUrl":"https://doi.org/10.1158/1538-7445.am2020-3801","url":null,"abstract":"Breast cancer stem cells (BCSCs) have been shown to be associated with tumor recurrence, metastasis and drug resistance. We reported that the ganglioside GD2 selectively identifies BCSCs and its over-expression in Triple-Negative Breast Cancer (TNBC). However, the factors regulating GD2+ BCSCs in a growing tumor are not known. Here we hypothesize that nutrient deprivation-induced oxidative stress upregulates GD2+ BCSCs in TNBC. TNBC cell lines including SUM159 and MDA-MB-231 were cultured under different nutrient-deprived conditions and analyzed for GD2 expression by flow cytometry. We have identified a steady increase of GD2+ cells from 5%±2% on day 3 to 20%±5% on day 6 in cells cultured in nutrient deprived condition. We further performed the in vivo by injecting GFP+ MDA-MB-231 cells into NSG mice and measured GD2+ expression in the growing tumor once a week. Interestingly, we also noticed a positive correlation between the percentage of GD2+ cells and tumor volume in vivo with r=0.9829 and pl0.0004 suggesting nutrient deprived conditions in the growing tumors results in higher GD2 expression. Next, the cells were cultured in medium with or without glucose or media containing 2-deoxy glucose (2DG, glycolysis inhibitor). We found that the percentage of GD2+ cells increased 2-fold in the absence of glucose or in the presence of 2DG (10mM) compared to cells cultured with glucose (6g/L) or without 2DG, suggesting that glucose deprivation enhances GD2 biosynthesis in TNBC cells. Global metabolomics profiling using liquid chromatography-mass spectrometry followed by KEGG pathway analysis identified signatures such as glutathione mediated detoxification and glutathione biosynthesis to be most highly upregulated in GD2+ compared to GD2- cells. As glutamine is a key precursor for glutathione biosynthesis, we cultured SUM159 and MDA-MB-231 cells in media with or without glutamine and found that the percentage of GD2+ cells positively correlates with glutamine concentration in the medium. Next, to target glutamine metabolism, we treated TNBC cells with glutaminase inhibitor, CB-839 or glutamine transporter inhibitor, V9302. This resulted in a 70-80% reduction of GD2 expression in a dose dependent manner. CB-839 and V9302 also inhibited mammosphere formation by 40-50% and increased reactive oxygen species (ROS) in a dose-dependent manner in TNBC cells. In conclusion, oxidative stress results in GD2+ BCSC phenotype in TNBC cells. Inhibition of glutamine uptake or its utilization by V9302 or CB-839 inhibits GD2+ BCSC phenotype and alters redox homeostasis in BCSCs by inducing ROS levels. Targeting glutamine transporter or glutaminase could complement conventional chemotherapy by targeting BCSCs in TNBC. Citation Format: Appalaraju Jaggupilli, Stanely J. Ly, Roshan Borkar, Khoa Nguyen, Bin Yuan, Nagireddy Putluri, Michael Andreeff, V. Lokesh Battula. Oxidative stress induces glutamine-dependent GD2+ triple negative breast cancer stem cells [abstract]. In: Pr","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90046066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 419: PKD1 regulates susceptibility to ulcerative colitis and colorectal cancer","authors":"A. Nikonova, Anna A. Kiseleva, A. Deneka, R. Tricarico, S. Grivennikov, E. Golemis","doi":"10.1158/1538-7445.am2020-419","DOIUrl":"https://doi.org/10.1158/1538-7445.am2020-419","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81814269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 1636: Diet-variants and immune characterization of a stage-defined, transgenic immunocompetent mouse model of HCC (ASV-B)","authors":"Annemilaï Tijeras-Raballand, C. Hobeika, P. Bonnin, B. Rousseau, Aurélie Rodrigues, Fouad Ladfil, M. Pocard, A. de Gramont, E. Raymond, S. Faivre, V. Paradis, C. Eveno","doi":"10.1158/1538-7445.am2020-1636","DOIUrl":"https://doi.org/10.1158/1538-7445.am2020-1636","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86850578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 661: Adipose specific monocyte chemotactic protein-1 knockdown reduces pulmonary metastasis of Lewis lung carcinoma in mice","authors":"Sneha Sundaram, Lin Yan","doi":"10.1158/1538-7445.SABCS18-661","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-661","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75152574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 3324: Non-invasive detection of aberrant DNA methylation in colorectal cancer by multiplex methylation specific PCR","authors":"Lili Ye, Chunting Zheng, Yuan Jie, Bin Li, Yuan Li, K. Hu, Liuhong Zeng, Yuying Wang, Mao Mao, P. Ding, T. Shi, M. Ye","doi":"10.1158/1538-7445.SABCS18-3324","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-3324","url":null,"abstract":"Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide, with an increasing prevalence. The 5-year relative survival rate for advanced stages is very low, with only 14% for stage IV. However, that of the early stage of CRC is about 90%. Therefore, it is important to screen CRC in the early stage. Epigenetic alterations linked to the carcinogenesis of CRC have been shown to occur earlier and more frequently than genetic alterations in CRC. Here, our study aims to develop a CRC screening methodology by applying the multiplex methylation specific PCR (MMSP) assay to detect CRC-specific methylation biomarkers, which has been pre-selected from public databases and subsequently validated in CRC samples of the Chinese population. Experimentally, cell free DNA (cfDNA) is extracted from ~4ml peripheral blood plasma. Following bisulfite conversion of the cfDNA, MMSP were applied to amplify and detect CRC-specific methylated CpG sites within the cfDNA. From the results of 28 CRCs and 52 control specimens, a sensitivity of 85.7% and the a specificity of 92.3% was achieved. Current standard and most widely used method of detecting CRC is colonoscopy screening. However, colonoscopy requires bowel preparation, and the sedation for patients is a complex and time-consuming procedure with high cost. Additionally, this invasive method also increases the possibility of infection and complications and patient compliance still largely remains a problem. Our non-invasive MMSP assay therefore provides an alternative non-invasive screening option that is cost-effective, meeting the urgent demand of early CRC detection. In addition, because colonoscopy screening currently has low adherence in Chinese population, our method holds great potential for increasing CRC screening rate in China. Citation Format: Lili Ye, Chunting Zheng, Yuan Jie, Bin Li, Yuan Li, Kunling Hu, Liuhong Zeng, Yuying Wang, Mao Mao, Peirong Ding, Taiping Shi, Mingzhi Ye. Non-invasive detection of aberrant DNA methylation in colorectal cancer by multiplex methylation specific PCR [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3324.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75216375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 1610: Getting under the skin: Fat quality in esophageal cancer prognosis","authors":"Maelle Anciaux, L. Ameye, T. Guiot, P. Flamen, S. Goldman, P. Demetter, A. Deleporte, A. Gossum, M. Paesmans, V. Donckier, A. Hendlisz, C. Vandeputte","doi":"10.1158/1538-7445.SABCS18-1610","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1610","url":null,"abstract":"INTRODUCTION The last few years have seen an increased interest in the role of body mass composition parameters in cancer survival. this study sought to assess the impact of the body mass composition (BMC) on prognosis of locally advanced esophageal cancer (EC) patients beyond the usual quantitative weight loss associated with this condition. METHODS Diagnostic CT scans were assessed for BMC in 155 all-stage EC patients at diagnosis. The index (area/height 2 ) of skeletal muscle (SMI), subcutaneous (SFI) and visceral fat (VFI) were delineated on two adjacent slides at the third lumbar vertebra level by two independent investigators using PLANET ONCO® software (DOSIsoft, France). Mean attenuation (or density) of fat tissue was measuring to assess the quality of adipose compartments. Survival and relapse free survival (RFS) were calculated from date of baseline CT-scan. RESULTS Interobserver correlations were excellent for all BMC parameters measured (r = 0.94 to 0.99). Remarkably, low subcutaneous fat density (SFD) was associated to better outcome, as were low disease stages. Low C-reactive protein (CRP) levels were also associated with better overall survival (OS). In contrast, low BMI did not affect the patients’ outcome. Relapse free survival (RFS) analysis showed that only high disease stages and SFD remained associated with poor RFS. Stepwise regression showed that the combination of SFD, stage and CRP was an effective model for OS prediction. No parameter was retained for RFS in the multivariate analysis. Detailed results are shown in Table 1. CONCLUSION SFD, stages and CRP appeared as robust prognostic factors of OS in EC patients, in contrast with BMI. While SFD and stages were significant in RFS univariate analysis, none of these two parameters were retained in multivariate analyses. These results confirm the validity of BMC assessment for evaluating patient prognosis and show for the first time that adipose tissues and inflammation may have a preponderant impact on cancer prognosis. Citation Format: Maelle Anciaux, Lieveke Ameye, Thomas Guiot, Patrick Flamen, Serge Goldman, Pieter Demetter, Amelie Deleporte, Andre Van Gossum, Marianne Paesmans, Vincent Donckier, Alain Hendlisz, Caroline Vandeputte. Getting under the skin: Fat quality in esophageal cancer prognosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1610.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"186 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75522131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB-249: Marine omega-3 fatty acid supplementation and risk of colorectal adenomas and serrated polyps: A randomized placebo-controlled trial","authors":"M. Song, I. Lee, J. Manson, J. Buring, R. Dushkes, David Gordon, J. Walter, K. Wu, A. Chan, S. Ogino, C. Fuchs, J. Meyerhardt, E. Giovannucci","doi":"10.1158/1538-7445.AM2019-LB-249","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-LB-249","url":null,"abstract":"BACKGROUND Marine omega-3 fatty acid (MO3FA) has been suggested to protect against colorectal cancer. However, the chemopreventive effect of MO3FA on precursors of colorectal cancer remains unclear. METHODS We assessed the effect of MO3FA supplementation on risk of conventional adenomas and serrated polyps, the two distinct subtypes of precursors of colorectal cancer, within the VITamin D and OmegA-3 TriaL (VITAL), a randomized, placebo-controlled, two-by-two factorial trial of MO3FA (1 g per day [460 mg EPA and 380 mg DHA]) and vitamin D3 (2000 IU per day) supplements among 25,871 Americans aged 50 years or older (including 5,106 blacks). Although regular screening endoscopy was not protocol-mandated during the study period, prior colonoscopy/sigmoidoscopy and other risk factors were well balanced by treatment group at baseline. When participants reported a diagnosis of polyp on the annual follow-up questionnaire, we requested permission to obtain endoscopic and pathologic records to confirm the diagnosis and extract the histopathologic information. Serrated polyps included hyperplastic polyps and mixed/serrated adenomas (traditional and sessile types). We calculated the odds ratios (ORs) and 95% confidence intervals (CIs) in relation to MO3FA treatment using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. We also performed subgroup analyses according to polyp features and participants’ characteristics. RESULTS During a median follow-up of 5.3 years, we documented 296 cases of colorectal adenomas in the intervention group and 306 in the control groups (multivariable OR=0.97, 95% CI, 0.83-1.14); and 178 and 170 cases of serrated polyps in the two groups, respectively (OR=1.05, 95% CI, 0.85-1.30). Similar null association was found for advanced adenomas (advanced histology or ≥10 mm) or high-risk serrated polyps (located in the proximal colon or ≥10 mm), or polyp subgroups according to size, location, multiplicity, or histology. When stratified by race/ethnicity, we found that MO3FA treatment was associated with lower risk of adenomas (OR=0.53, 95% CI, 0.31-0.91) and serrated polyps (OR=0.54, 95% CI, 0.27-1.10) in African Americans, whereas no association was found in non-Hispanic whites or other racial/ethnic groups (P for interaction=0.06 for adenomas and 0.15 for serrated polyps). No interaction was detected with other demographic factors, colorectal cancer risk factors, endoscopic use, baseline fish intake, or plasma MO3FA levels. CONCLUSIONS Supplementation with marine omega-3 fatty acids at a dose of 1 g per day was not associated with risk of colorectal premalignant lesions. A potential benefit among African Americans requires further confirmation. Citation Format: Mingyang Song, I-Min Lee, JoAnn E. Manson, Julie E. Buring, Rimma Dushkes, David Gordon, Joseph Walter, Kana Wu, Andrew T. Chan, Shuji Ogino, Charles S. Fuchs, Jeffrey A. Meyerhardt, Edward L. Giovannucci. Marine omega-3 fa","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75549805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PL04-02: HIV malignancies: From despair to gene therapy","authors":"A. Noy","doi":"10.1158/1538-7445.SABCS18-PL04-02","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-PL04-02","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81879488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB-252: Group-based smoking cessation treatment for incarcerated men: A pilot study","authors":"Pamela Valera, Nicholas Acuna","doi":"10.1158/1538-7445.AM2019-LB-252","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-LB-252","url":null,"abstract":"Introduction. Cigarette smoking is the leading cause of morbidity and mortality that contributes to over six million deaths worldwide and is projected to cause more than eight million deaths per year by 2030. Overall cigarette smoking rates in the United States (U.S.) is estimated at 14%, but this number increases to 50-83% of smokers within correctional populations. Methods. Using a cohort study design, sixteen incarcerated male smokers from a Northeastern state maximum prison facility in the U.S. participated in a 4-week group-based smoking cessation treatment program with nicotine replacement therapy and a one-month follow-up period to determine quit behaviors and abstinence. The goal of this pilot study was to explore the feasibility, acceptability, and efficacy of a smoking cessation group treatment intervention for incarcerated smokers where tobacco products are permitted. Results. In this feasibility study, the average age of participants enrolled was 43 (SD = 13.69), and their first incarceration was at 19 (SD = 7.30). The majority of the participants identified as African American/Black (62.5%), 31.3% identified as Caucasian/White, and 6.3% identified as Hispanic/Latino as their race/ethnicity. The average age where individuals started smoking was 13.8 (SD = 3.2) and the total number of years smoked is 25.6 (SD = 14.9). The mean of cigarettes smoked each day was 13.0 (SD = 9.8). More than half of the people in the study indicated that they relight their cigarettes. Additionally, the two brands that participants indicated as their favorite were Kite (18.8%) and Newport (68.8%). Of all the participants, 87.5% indicated that they smoked menthol cigarettes. Majority of the participants indicated the importance of quitting tobacco (8.80 ± 1.82) and that they had a very difficult time during their previous quit attempts (43.8%). Previous quit attempts included forced abstinence while in solitary confinement or administrative segregation. At the 4-week follow up period, half of the participants that were enrolled in the group-based smoking cessation treatment and completed the program indicated that they did not smoke or use tobacco in the past 7-days or since their initial quit date (50.0%). Conclusion. Group-based smoking cessation treatment should be prioritized as an effective intervention to aid incarcerated smokers to quit smoking. This study builds upon our growing knowledge of tobacco dependence and smoking cessation treatment, with a focus on individuals involved in the criminal justice system. Citation Format: Pamela Valera, Nicholas Acuna. Group-based smoking cessation treatment for incarcerated men: A pilot study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-252.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84237767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 3323: The feasibility for detecting hereditary genetic findings of familial gastric cancer","authors":"Sadaaki Nishimura","doi":"10.1158/1538-7445.AM2019-3323","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-3323","url":null,"abstract":"Background: Multiplex gene panel tests using next-generation sequencing has currently been clinically available for various cancer patients including gastric cancer in Japan. The original purpose of the Multiplex gene panel tests is to find actionable genetic alterations which might correlate with promising therapeutic antitumor drugs. Accordingly, secondary genetic findings as germline mutation which is associated with hereditary disease may also be detectable by the Multiplex gene panel tests. It has been reported that familial cancers represent around 5%–10% of all cancer patients. Gastric cancer is one of popular cancers in Japan. The prediction of patients with familial gastric cancer (FGC) before the multiplex gene panel tests might be important for the gene consultation for the patients and their family. Objective: The aim of study is to clarify the characteristic clinico-pathologic features of FGC to predict the possibility of hereditary gastric cancer. Patients and Methods: A total of 2301 gastric cancer patients who received gastrectomy at our department was enrolled in this study. We classified FGCs into 2 categories by modification of International Gastric Cancer Linkage Consortium (IGCLC) which excluded pathogenic types, as follows, group A: gastric cancer in an individual under the age of 40; group B: two gastric cancer cases in a family regardless of age. In contrast, the most gastric cancers were sporadic, which was classified as group C. The clinicopathological factors including E-cadherin and p53 expression by immunostaining, was retrospectively compared among 3 groups. Results: One hundred and fifty-two cases (6.6%) of 2301 patients were classified as FGCs (group A: 71 cases; group B: 81 cases), whereas the remaining 2149 patients were classified as group C (93.4%). Female (43.4%) and diffuse-type gastric cancer (57.2%) was significantly (p Conclusion: Young age ( Citation Format: Sadaaki Nishimura. The feasibility for detecting hereditary genetic findings of familial gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3323.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84899091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}